CD27 expressing Hematologic Malignancies
Showing 1 - 25 of 4,985
CD19 Expressing Malignancies, Hematologic Malignancy Trial in United States (PBCAR19B)
Recruiting
- CD19 Expressing Malignancies
- Hematologic Malignancy
- PBCAR19B
-
Gilbert, Arizona
- +6 more
Nov 8, 2022
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)
Recruiting
- Non-hodgkin Lymphoma
- +2 more
- CC312
-
Tianjin, Tianjin, ChinaInstituteHBDH
Sep 12, 2023
Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)
Recruiting
- Hematologic Malignancies
- RD13-02 cell infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jun 26, 2023
Blood Cancer Trial (KCAT19 T cells)
Not yet recruiting
- Blood Cancer
- KCAT19 T cells
- (no location specified)
May 20, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Cyclophosphamide (Non-IMP, Lymphodepletion)
- +3 more
-
Ulm, Baden-Württemberg, Germany
- +4 more
Jul 24, 2023
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)
Not yet recruiting
- Hematopoietic Stem Cell Transplantation
- Hematologic Malignancy
- CliniMACS®
- (no location specified)
Oct 17, 2023
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Hematologic Malignancies Trial in Assiut (CD56)
Recruiting
- Hematologic Malignancies
- CD56
-
Assiut, Egypt
- +1 more
Jul 20, 2022
Adult Relapsed/Refractory B-cell Hematologic Malignancies Trial in Beijing (CD19-CAR-NK)
Recruiting
- Adult Relapsed/Refractory B-cell Hematologic Malignancies
- CD19-CAR-NK
-
Beijing, Beijing, ChinaThe Fifth Medical Center of Chinese People's Liberation Army (PL
Dec 1, 2022
B-Cell Lymphoblastic Leukemia/Lymphoma Trial in Kunming (Anti-CD19 UCAR-NK cells)
Recruiting
- B-Cell Lymphoblastic Leukemia/Lymphoma
- Anti-CD19 UCAR-NK cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 19, 2022
Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- allogenic CD19-CAR-NK cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023
B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)
Withdrawn
- B-cell Lymphoma
- B-cell Leukemia
- anti-CD19 UCAR-NK cells
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
Hematological Malignancies Trial (Anti-CD7 CAR-T)
Not yet recruiting
- Hematological Malignancies
- Anti-CD7 CAR-T
- (no location specified)
Jul 8, 2022
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)
Not yet recruiting
- NHL, Relapsed, Adult
- +3 more
- KUR-502
- (no location specified)
Aug 2, 2022
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia Trial in Miami (device, procedure, drug)
Withdrawn
- Hematologic Diseases
- +5 more
- CliniMACS
- +7 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Sep 26, 2022
Pediatric Hematologic Malignancies Trial in Saint Louis (Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs
Not yet recruiting
- Pediatric Hematologic Malignancies
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
-
Saint Louis, MissouriWashington University School of Medicine
Jul 20, 2022
Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Jun 8, 2023
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor Trial in United
Completed
- Acute Myelogenous Leukemia
- +3 more
- XmAb14045
-
Jacksonville, Florida
- +8 more
Mar 4, 2022
Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies Trial in Langfang (anti-CD33 CAR T cells)
Not yet recruiting
- Relapsed and/or Refractory Acute Myeloid Leukemia
- High Risk Hematologic Malignancies
- anti-CD33 CAR T cells
-
Langfang, Hebei, ChinaHebei Yanda Lu Daopei Hospital
Jun 30, 2022
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)
Recruiting
- Relapsed/Refractory, High Risk Hematologic Malignancies
- T-ALL/Lymphoma
- CD7CAR T cells
-
Langfang, Hebei, ChinaHebei Yanda Lu Daopei Hospital
Jun 30, 2022
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Hematologic Malignancies Trial in Hangzhou (RD13-01 cell infusion)
Completed
- Hematologic Malignancies
- RD13-01 cell infusion
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Jan 8, 2022
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New
Recruiting
- Mantle-cell Lymphoma
- B Cell Chronic Lymphocytic Leukemia
-
Monza, MB, ItalyAndrea Aroldi
May 24, 2023